Del Mar Pharmaceuticals Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (14)

Latest Posts

About This Stock More About This Stock
Week In Review: Sorrento Therapeutics Fights $933 Million Take-Private Bid
Article By: ChinaBio® Today
Saturday, February 1, 2020 5:24 PM EDT
Sorrento Therapeutics, a San Diego-Nanjing-Suzhou biopharma, rejected a $7 per share take-private offer from an unnamed PE company that valued the company at $933 million. Sorrento reported a loss of $57 million over the last 12 months.
In this article: AZN, ROG, SRNE, DMPI, EYPT
Read
Week In Review: Zai Lab Completes $150 Million US IPO; Investors Push Valuation To $1.4 Billion
Article By: ChinaBio® Today
Saturday, September 23, 2017 5:03 PM EDT
Zai Lab raised $150 million in its US IPO after the company increased the size of the offering to 8 million shares. Demand for the offering was strong, and Zai's stock opened 50% above the IPO price at $27 per share.
In this article: MRK, ZLAB, DMPI
Read
Week In Review: Vivace Details Its Capital Efficient Plan To Develop Novel Cancer Therapies
Article By: ChinaBio® Today
Saturday, July 29, 2017 1:39 PM EDT
In June, Vivace Therapeutics burst its stealth bubble by announcing it had raised $40 million in venture capital.
In this article: DMPI, SRTS
Read
Week In Review: China Issues Rules For Trials Of Stem Cell Treatments
Article By: ChinaBio® Today
Saturday, September 12, 2015 3:00 PM EDT
Under the new rules, clinical trials must be conducted in Tier IIIa hospitals, records kept for 30 years, an ethics panel must oversee the trial, certified stem cell lines must be used, and patients must be monitored after treatment ends.
In this article: DVA, MR, DMPI
Read

PARTNER HEADLINES

Latest Tweets for $DMPI

No tweets yet!